Objectives

1. Develop innovative theranostic solutions by:  

• Updating MeMRI components and technologies for application as Clinical Investigational Device in multiple hospitals, and  
• Use of MeMRI in an observational clinical study with lutetium-177-PSMA treatment in metastatic prostate cancer patients to demonstrate improved patient selection and monitoring.
• Explore the value of Chemical Exchange by Saturation Transfer (CEST) and Amide Proton Transfer (APT) technology in the context of lutetium-177-PSMA treatment decision making

2. Develop quantification & decision-making models, and broadly applicable MeMRI decision-making tools. This will aid in:

• Personalizing the lutetium-177-PSMA treatment and disease management of patients with metastatic prostate cancer, and  
• Reducing the required supply of radioisotopes based on improved patient stratification, dosing and cessation of treatment, resulting in reduction of general use of therapeutics.

3. Broaden the availability of MeMRI technology by facilitating its application across different MRI manufacturers and magnet field strengths (translation to widely available 3T MRI scanners).

4. Improve treatment manufacturing capacity by:

• Increasing lutetium-177 production capacity, including the development of a recycling process for the starting material Ytterbium, and
• Developing expertise on centralised preparation of lutetium-177 radiopharmaceuticals.